Anal Canal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Anal Canal Carcinoma

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 57 12 13 44 15
Anal Canal Cancer 12 15
Anal Canal and Perianal Gland Carcinoma 12
Carcinoma of the Anal Canal 58
Cancer of the Anal Canal 36
Carcinoma of Anal Canal 70



57 (Updated 20-May-2021)
autosomal dominant


anal canal carcinoma:
Inheritance autosomal dominant inheritance


Orphanet: 58  
Rare gastroenterological diseases

External Ids:

Disease Ontology 12 DOID:0050688 DOID:6126
OMIM® 57 105580
KEGG 36 H00044
MeSH 44 C563020
NCIt 50 C7489
SNOMED-CT 67 285310000
ICD10 32 C21.1
UMLS via Orphanet 71 C0563211
Orphanet 58 ORPHA424013
MedGen 41 C0563211
SNOMED-CT via HPO 68 263681008
UMLS 70 C0563211

Summaries for Anal Canal Carcinoma

KEGG : 36 Squamous cell carcinoma of the anal canal accounts for 1.5 per cent of all digestive system cancers in the USA, with an estimated 4,660 new cases and 660 deaths in 2006. Epidemiological and molecular-biology studies have now shown that sexually transmitted infection with human papillomavirus (HPV) is the most important aetiological agent. Human immunodeficiency virus (HIV) infection is also associated with anal cancer. HPV infection is transient in most immunocompetent individuals, but HIV-positive patients have evidence of persistent HPV infection within the anal canal. Current data suggest that mutations in p53, DCC and APC tumor suppressor genes contribute to the stepwise progression of anal squamous cell carcinoma in immunocompetent individuals.

MalaCards based summary : Anal Canal Carcinoma, also known as anal canal cancer, is related to mucoepidermoid carcinoma and keratinizing squamous cell carcinoma. An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma), and among its related pathways/superpathways is Viral carcinogenesis. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and lymph node, and related phenotype is anal canal squamous carcinoma.

Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

More information from OMIM: 105580

Related Diseases for Anal Canal Carcinoma

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 30.6 KRT7 KRT13 CDKN2A
2 keratinizing squamous cell carcinoma 30.6 KRT7 CDKN2A
3 anus cancer 30.6 KRT7 CDKN2A CAGE1
4 small cell carcinoma 30.5 KRT7 KRT20 CDKN2A
5 basaloid squamous cell carcinoma 30.3 KRT7 KRT20 KRT13 CDKN2A
6 human papillomavirus infectious disease 30.2 KRT13 CDKN2A
7 adenoid cystic carcinoma 30.1 KRT7 KRT20 CDKN2A
8 merkel cell carcinoma 30.1 KRT7 KRT20 CDKN2A
9 mammary paget's disease 29.9 PIP KRT7 KRT20
10 squamous cell carcinoma 29.9 NME1 KRT7 ING1 CDKN2A
11 transitional cell carcinoma 29.9 NME1 KRT7 KRT20 CDKN2A
12 papilloma 29.8 KRT7 KRT20 KRT13 CDKN2A
13 colorectal adenocarcinoma 29.5 KRT7 KRT20 CDX2 CDKN2A
14 adenocarcinoma 29.4 KRT7 KRT20 CDX2 CDKN2A
15 anal canal adenocarcinoma 29.3 PIP KRT7 KRT20 CDX2
16 signet ring cell adenocarcinoma 29.3 PIP KRT7 KRT20 CDX2
17 rectum adenocarcinoma 28.9 PIP KRT7 KRT20 CDX2 CAGE1
18 neuroendocrine carcinoma 10.5
19 anal canal squamous cell carcinoma 10.4
20 rare tumor 10.3
21 cervical basaloid squamous cell carcinoma 10.3 KRT7 CDKN2A
22 inverted transitional papilloma 10.3 KRT7 CDKN2A
23 cervical adenoid cystic carcinoma 10.3 KRT7 CDKN2A
24 apocrine adenocarcinoma 10.3 PIP KRT7
25 papillary squamous carcinoma 10.3 KRT7 CDKN2A
26 gallbladder adenoma 10.2 KRT7 CDKN2A
27 vulvar eccrine porocarcinoma 10.2 PIP CDKN2A
28 clear cell adenocarcinoma 10.2 KRT7 KRT20
29 ceruminoma 10.2 PIP KRT7
30 malignant acrospiroma 10.2 PIP KRT7
31 oncocytic breast carcinoma 10.2 PIP KRT7
32 ceruminous adenocarcinoma 10.2 PIP KRT7
33 cutaneous mucoepidermoid carcinoma 10.2 PIP KRT7
34 middle ear carcinoma 10.2 KRT7 CDKN2A
35 vulval paget's disease 10.2 PIP KRT7
36 eccrine adenocarcinoma 10.2 PIP KRT7
37 toxic shock syndrome 10.2
38 anal margin carcinoma 10.2
39 adenosquamous carcinoma 10.2
40 lymphopenia 10.2
41 acquired immunodeficiency syndrome 10.2
42 neutropenia 10.2
43 urethral villous adenoma 10.2 KRT7 KRT20
44 breast mucinous carcinoma 10.2 PIP KRT7
45 erysipeloid 10.2 PIP KRT7
46 clear cell hidradenoma 10.2 PIP KRT7
47 hidradenoma 10.2 PIP KRT7
48 hidrocystoma 10.2 PIP KRT7
49 bladder benign neoplasm 10.2 KRT7 KRT20
50 nephrogenic adenoma of urinary bladder 10.2 KRT7 KRT20

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:

Diseases related to Anal Canal Carcinoma

Symptoms & Phenotypes for Anal Canal Carcinoma

Human phenotypes related to Anal Canal Carcinoma:

# Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 31 HP:0006763

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
anal canal squamous carcinoma

Clinical features from OMIM®:

105580 (Updated 20-May-2021)

Drugs & Therapeutics for Anal Canal Carcinoma

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
4 Antimetabolites Phase 3
5 Immunosuppressive Agents Phase 3
6 Immunologic Factors Phase 3
7 Albumin-Bound Paclitaxel Phase 3
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
Fluorouracil Approved Phase 2 51-21-8 3385
Ipilimumab Approved Phase 2 477202-00-9
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
Mitoguazone Investigational Phase 2 459-86-9
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
16 Antibiotics, Antitubercular Phase 2
17 Mitomycins Phase 2
18 Alkylating Agents Phase 2
19 Anti-Bacterial Agents Phase 2
20 Liver Extracts Phase 2
21 Immunoglobulins Phase 2
22 Antibodies Phase 2
23 Antibodies, Monoclonal Phase 2
24 Antimitotic Agents Phase 2
25 Tubulin Modulators Phase 2
26 taxane Phase 2
27 Antineoplastic Agents, Immunological Phase 2
28 Tempol Investigational Phase 1 2226-96-2
29 Protective Agents Phase 1
30 Antioxidants Phase 1
31 Neuroprotective Agents Phase 1
32 Radiation-Protective Agents Phase 1
nivolumab Approved 946414-94-4

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
2 Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study Completed NCT00003652 Phase 3 cisplatin;fluorouracil
3 A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) Recruiting NCT04472429 Phase 3 carboplatin;paclitaxel;retifanlimab
4 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
5 A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
6 A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
7 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
8 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
9 A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Recruiting NCT02314169 Phase 2
10 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
11 Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors Recruiting NCT02185443 Phase 2
12 Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
13 A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202) Active, not recruiting NCT03597295 Phase 2 Retifanlimab
14 Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma. Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
15 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
16 A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal Terminated NCT01382745 Phase 2 Nimotuzumab
17 An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal Withdrawn NCT04499352 Phase 2 BI 754091;BI 836880
18 A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal Terminated NCT01324141 Phase 1 Tempol;5-Fluorouracil;Mitomycin-C
19 A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal Unknown status NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
20 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Completed NCT01845779 DCF regimen
21 Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates Completed NCT03465501
22 Immunomonitoring and Biomarker Research Based on Tumor and Blood Samples in Patients With Squamous Cell Anal Carcinoma Not yet recruiting NCT03942900

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Genetic Tests for Anal Canal Carcinoma

Anatomical Context for Anal Canal Carcinoma

MalaCards organs/tissues related to Anal Canal Carcinoma:

Lung, Breast, Lymph Node, Liver, Appendix, Skin, Prostate

Publications for Anal Canal Carcinoma

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 321)
# Title Authors PMID Year
Recurrent deletions of chromosomes 11q and 3p in anal canal carcinoma. 61 57
3570551 1987
[A Case of Long-Term Survival after Multidisciplinary Treatment for Neuroendocrine Carcinoma of the Anal Canal]. 61
33790167 2021
Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy. 61
33723132 2021
Pushing the limits for the treatment of anal canal cancer. 61
32621154 2021
Tailoring the radiotherapy approach in patients with anal squamous cell carcinoma based on inguinal sentinel lymph node biopsy. 61
32964456 2021
Laparoscopic abdominosacral resection for rectal and anal canal carcinoma with pagetoid spread. 61
32875728 2020
Induction Chemotherapy in Patients With Anal Canal Cancer: A Pilot Study. 61
32381433 2020
Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation. 61
32417349 2020
Case of Complete Remission After Volumetric Modulated Arc Therapy to Primary Tumor Alone in Locally Advanced Anal Canal Cancer With Active AIDS and Low CD4 Cell Count: Longest Survival in History? 61
32789041 2020
[Metastatic squamous cell carcinomas of the anal canal: Current management and prospects]. 61
32591138 2020
[A Case Report of Brain Metastasis from Anal Canal Carcinoma]. 61
32694228 2020
Anal canal adenocarcinoma with pagetoid spread and inguinal lymph node metastasis treated with preoperative chemoradiotherapy: A case report. 61
32337034 2020
Anal Cancer. 61
32402305 2020
Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. 61
32036405 2020
HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake. 61
32193623 2020
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure. 61
31809980 2020
Difference in toxicity between HIV-positive and HIV-negative patients with squamous-cell cancer of the anal canal treated with concomitant radio-chemotherapy. 61
32175102 2020
Anal canal cancer in Brazil: why should we pay more attention to the epidemiology of this rare disease? 61
32565890 2020
A case report of anal canal cancer with pagetoid spread requiring differential diagnosis. 61
32961459 2020
MR staging of anal cancer: what the radiologist needs to know. 61
31041496 2019
Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). 61
31185328 2019
Long-term results achieved by guideline-based stage-dependent management of anal cancer in a non-HIV population. 61
31641849 2019
Sweet syndrome and erythema nodosum in a case of anal canal cancer during concomitant radiochemotherapy. 61
31617491 2019
Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal. 61
31548820 2019
Successful Treatment of Anal Canal Cancer Metastasis to the Cranial Bones: A Case Report and Literature Review. 61
31280229 2019
Long-term outcomes after surgical dissection of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma. 61
31340778 2019
Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review. 61
30825391 2019
Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. 61
30608547 2019
Prognostic significance of inflammatory-related parameters in patients with anal canal cancer. 61
30617412 2019
Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. 61
30911306 2019
MRI evaluation of anal and perianal diseases. 61
30582572 2019
Accuracy of Anal Cytology for Diagnostic of Precursor Lesions of Anal Cancer: Systematic Review and Meta-analysis. 61
30451747 2019
[Two Cases of Anal Canal Adenocarcinoma with Pagetoid Spread Treated with Laparoscopic Abdominoperineal Resection]. 61
30692326 2018
Definitive chemoradiotherapy for anal canal cancer: single-center experience. 61
29992389 2018
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). 61
30172453 2018
Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. 61
29891206 2018
Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report. 61
30458812 2018
[Anal canal cancer: In the era of intensity-modulated radiotherapy, outstanding issues]. 61
30181029 2018
Intensity-modulated radiotherapy for synchronous cancer of the anal canal and cervix. 61
30197673 2018
Association between Human Papillomavirus and Non-cervical Genital Cancers in Brazil: A Systematic Review and Meta-Analysis 61
30255688 2018
Synchronous anal canal carcinoma in a heterosexual couple. 61
30200930 2018
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. 61
30128811 2018
Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer. 61
27755059 2018
Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes? 61
28948325 2018
Use of Indirect Target Gating in Magnetic Resonance-guided Liver Stereotactic Body Radiotherapy: Case Report of an Oligometastatic Patient. 61
29750133 2018
Anal canal squamous cell cancer: are surgical alternatives to chemoradiation just as effective? 61
29270784 2018
A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer. 61
30034895 2018
PET imaging in anal canal cancer: a systematic review and meta-analysis. 61
28972796 2017
[Multidisciplinary Treatment for Squamous Cell Carcinoma of the Anal Canal]. 61
29394850 2017
[A Case of Anal Canal Cancer with Skin Invasion to Which Abdominoperineal Resection and Perineum Reconstruction Were Performed after Neoadjuvant Chemoradiotherapy]. 61
29394843 2017

Variations for Anal Canal Carcinoma

Expression for Anal Canal Carcinoma

Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for Anal Canal Carcinoma

Pathways related to Anal Canal Carcinoma according to KEGG:

# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

GO Terms for Anal Canal Carcinoma

Cellular components related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.92 NME1 KRT7 KRT20 KRT13

Biological processes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.13 KRT7 KRT20 KRT13
2 cornification GO:0070268 8.8 KRT7 KRT20 KRT13

Sources for Anal Canal Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....